Evaluating the adenosine hypothesis of restless legs syndrome and its implications for current and future treatment strategies

Expert Review of Neurotherapeutics · Published 2025-12-13 · DOI 10.1080/14737175.2025.2603544

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1080/14737175.2025.2603544

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• The evolving treatment landscape of restless legs syndrome · Therapeutic Advances in Neurological Disorders · 2026 · Cites or is cited by this article
• Medication-overuse headache: can anti-CGRP monoclonal antibodies replace withdrawal? · Expert Review of Neurotherapeutics · 2025 · Same journal
• A conceptual framework based on current and emerging treatments for treatment-resistant depression: mechanistic evolution, clinical evidence, and future directions · Expert Review of Neurotherapeutics · 2026 · Same journal
• Optimizing cognitive behavioral therapy to treat anxiety among youth with autism spectrum disorders · Expert Review of Neurotherapeutics · 2025 · Same journal
• An update on the comorbidity of attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and its clinical management · Expert Review of Neurotherapeutics · 2025 · Same journal
• Building a new arsenal: repurposed drugs and metronomic chemotherapy against medulloblastoma · Expert Review of Neurotherapeutics · 2026 · Same journal
• Contemporary and evolving perspectives on surgical therapies for essential tremor: deep brain stimulation and focused ultrasound · Expert Review of Neurotherapeutics · 2026 · Same journal
• The latest views on how vagus nerve stimulation works in epilepsy: a plain language summary · Expert Review of Neurotherapeutics · 2025 · Same journal
• Advances in targeted closed loop spinal cord stimulation to treat pain of the trunk and limbs · Expert Review of Neurotherapeutics · 2026 · Same journal
• Speech and language outcome measures in clinical trials of Alzheimer’s and Parkinson’s diseases · Expert Review of Neurotherapeutics · 2025 · Same journal